AkandaSTU:Y232 21 Net Margin % is -17,405.91% as of Dec. 2025. GuruFocus rates STU:Y232 with a GF Score™ of 21/100. The stock has 9 warning signs investors should review. Among 956 Drug Manufacturers companies, Akanda ranks worse than 99.16% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Akanda's Net Income for the
six
months ended in Dec. 2025 was €-38.29 Mil. Akanda's Revenue for the
six
months ended in Dec. 2025 was €0.22 Mil. Therefore, Akanda's net margin for the quarter that ended in Dec. 2025 was -17,405.91%.
The historical rank and industry rank for Akanda's Net Margin % or its related term are showing as below:
STU:Y232'
s Net Margin % Range Over the Past 10 Years
Min: -115050 Med: -17695.35 Max: -444.96
Current: -17695.35
STU:Y232's Net Margin % is ranked worse than 99.16% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs STU:Y232: -17695.35
Akanda (STU:Y232) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Akanda Net Margin % Related Terms
Akanda Net Margin % Historical Data
* Premium members only.
The historical data trend for Akanda's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:Y232 vs BFRI, BIOE, CABR: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Akanda's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akanda Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akanda's Net Margin % distribution charts can be found below:
* The bar in red indicates where Akanda's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akanda (STU:Y232) has a Net Margin % of -17,405.91% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Akanda and its competitors. According to the industry distribution chart, Akanda ranks #948 out of 956 companies in the Drug Manufacturers industry, placing it in the top 99.2%.
Is Akanda's Net Margin % too high?
Akanda's current Net Margin % is -17,405.91%. Based on the distribution chart, Akanda ranks #948 out of 956 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Akanda has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Akanda's Net Margin % compare to BFRI and BIOE?
According to the Drug Manufacturers industry distribution chart, Akanda ranks #948 out of 956 companies for Net Margin %. This places Akanda in the lower half of its industry. The industry median Net Margin % is 5.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Akanda and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akanda's current Net Margin % is -17,405.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akanda stock overvalued right now?
Akanda (STU:Y232) has a current Net Margin % of -17,405.91%. The current Net Margin % is -17,405.91%. Akanda's overall GF Score™ is 21/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Akanda (STU:Y232), the current Net Margin % is -17,405.91% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Akanda Corp is a cannabis cultivation, manufacturing, and distribution company. The company is a medical cannabis & hemp and wellness platform company seeking to help people lives through improved access to high-quality and affordable products. The Company is also in the business of leasing fiber optic networks and telecommunication towers, through its subsidiary. The company has four reportable segments: Infrastructure, Cultivation, Distribution, and Corporate. A majority of its revenue is generated from the Infrastructure segment, which relates to the leasing and/or rental of fiber optic networks and telecommunication towers at First Towers in Mexico.
21GF Score
Get the complete analysis for STU:Y232
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:Y232 has been successfully added to your 
